These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 31823525)

  • 21. Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers.
    Younis IR; Kirby BJ; Billin AN; Xiao D; Song Q; Watkins TR; Othman AA
    Clin Transl Sci; 2023 Mar; 16(3):536-547. PubMed ID: 36573450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
    Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
    Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
    Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
    Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
    Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
    Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.
    Merali S; Wang Z; Frost C; Meadows-Shropshire S; Hawthorne D; Yang J; Seiffert D
    Platelets; 2023 Dec; 34(1):2222846. PubMed ID: 37394920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
    Wu J; Zhou R; Zhang Q; Zhang Q; Qin H; Ye Z; Xu Y; Feng S; Shu C; Shen Y; Fan Y; Wang Q; Du Y; Hu W
    Diabetes Obes Metab; 2024 Mar; 26(3):901-910. PubMed ID: 38100147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration.
    Scott G; Osborne SA; Greig G; Hartmann S; Ebelin ME; Burtin P; Rappersberger K; Komar M; Wolff K
    Clin Pharmacokinet; 2003; 42(14):1305-14. PubMed ID: 14606933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study.
    Xu J; Zhang H; Chen H; Zhu X; Jia H; Xu Z; Huo D; Zhang H; Li C; Ding Y
    Ann Med; 2023; 55(2):2264850. PubMed ID: 38071661
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers.
    Naik H; Steiner DJ; Versavel M; Palmer J; Fong R
    Clin Transl Sci; 2021 Jul; 14(4):1272-1279. PubMed ID: 33278330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.
    Sanyal AJ; Lopez P; Lawitz EJ; Lucas KJ; Loeffler J; Kim W; Goh GBB; Huang JF; Serra C; Andreone P; Chen YC; Hsia SH; Ratziu V; Aizenberg D; Tobita H; Sheikh AM; Vierling JM; Kim YJ; Hyogo H; Tai D; Goodman Z; Schaefer F; Carbarns IRI; Lamle S; Martic M; Naoumov NV; Brass CA
    Nat Med; 2023 Feb; 29(2):392-400. PubMed ID: 36797481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study.
    Ito M; Tauscher-Wisniewski S; Smulders RA; Wojtkowski T; Yamada A; Koibuchi A; Uz T; Marek GJ; Goldwater RD
    Muscle Nerve; 2022 Jan; 65(1):110-120. PubMed ID: 34642949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study.
    Zhu X; Wu M; Wang H; Li H; Lin J; Peng Y; Hu Y; Li C; Ding Y
    Expert Opin Investig Drugs; 2021 May; 30(5):579-589. PubMed ID: 33682556
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults.
    Lee CA; Schreiber S; Bressler B; Adams JW; Oh DA; Tang YQ; Zhang J; Komori HK; Grundy JS
    Clin Pharmacol Drug Dev; 2024 May; 13(5):534-548. PubMed ID: 38345530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers.
    Modi NB; Cheng X; Mattheakis L; Hwang CC; Nawabi R; Liu D; Gupta S
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1263-1278. PubMed ID: 33942566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers.
    Wang Y; Crittenden DB; Eng C; Zhang Q; Guo P; Chung D; Fenaux M; Klucher K; Jones C; Jin F; Quirk E; Charlton MR
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1198-1208. PubMed ID: 34302449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.